<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570349</url>
  </required_header>
  <id_info>
    <org_study_id>INOT 50</org_study_id>
    <nct_id>NCT00570349</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis</brief_title>
  <official_title>Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to assess the safety and tolerability of inhaled nitric
      oxide (NO) when administered by nasal cannula over a 44 hour period to clinically stable
      Cystic Fibrosis (CF) subjects. Toxicity is to be defined as a drop in oxygen saturations, a
      decline in forced expiratory volume in one second (FEV1), or an increase in methemoglobin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the gene
      encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein. A cycle of
      chronic, persistent infections with CF-related pathogens and an excessive inflammatory
      response progressively damages the airways and lung parenchyma, resulting in widespread
      bronchiectasis and ultimately, respiratory failure. Despite tremendous advances in
      understanding the CF gene and the CFTR protein, it is not known exactly how mutations in the
      gene and defects in CFTR lead to persistent airway infection and inflammation.

      Inhaled nitric oxide (NO) has potential to be an effective treatment in CF lung disease.
      Inhaled NO has been studied in other airways diseases characterized by infection and /or
      inflammation such as COPD and idiopathic pulmonary fibrosis.

      NO has been shown to activate CFTR and alternative chloride channels, thereby increasing
      chloride current in epithelial cells. Therefore, NO treatment may be beneficial in
      individuals with CF.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of Drug, Assessed by Change in Methemoglobin Levels</measure>
    <time_frame>Baseline and 48 hours</time_frame>
    <description>Methemoglobin level assessments were measured through blood draws - hematology. This test measures the amount of methemoglobin (a type of hemoglobin that is unable to transport oxygen to tissues) in blood. Normal methemoglobin percentage range 1% - 2%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Oxygen Saturation</measure>
    <time_frame>Baseline and 48 hours</time_frame>
    <description>Safety and tolerability of drug assessed by decreased oxygen saturation was measured through pulse oximeter, which measure the amount of oxygen in the blood.
Normal range percentage is 95 - 100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline and 48 hours</time_frame>
    <description>Decrease in forced expiratory volume in 1 second was measured through spirometer. Spirometer measures the volume of air inspired and expired by the lungs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the Difference in Sputum Bacterial Density Before and After NO Inhalation. Assess the Difference in Lower Airway Inflammatory Measures Before and After NO Inhalation</measure>
    <time_frame>44 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Low Dose Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the low dose cohort receive 20 part per million (ppm) of nitric oxide via nasal cannula over a 44 hour period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the high dose cohort receive 40 ppm of nitric oxide via nasal cannula over a 44 hour period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitrogen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100% Nitrogen (placebo) will be administer at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide for Inhalation</intervention_name>
    <description>Nitric oxide will be administered at 20 ppm via nasal cannula over a 44 hour period.</description>
    <arm_group_label>Low Dose Cohort</arm_group_label>
    <other_name>INO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide for Inhalation</intervention_name>
    <description>Nitric oxide will be administered at 40 ppm via nasal cannula over a 44 hours period.</description>
    <arm_group_label>High-Dose Cohort</arm_group_label>
    <other_name>INO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrogen</intervention_name>
    <description>100% nitrogen (placebo) will be administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.</description>
    <arm_group_label>Nitrogen</arm_group_label>
    <other_name>Nitrogen (N2) Grade 5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of CF

          -  12 years of age and older

          -  FEV1 greater than 40% of predicted

          -  Resting awake oxygen saturation of at least 88%

          -  Stable pulmonary disease as defined by both clinical impression and having had no
             recent hospitalizations or changes in antibiotic regimen within 1 month prior to
             enrollment

          -  Signed informed consent form

        Exclusion Criteria:

          -  Pulmonary exacerbation resulting in antibiotic treatment (except prophylactic
             antibiotics) within 1 month of enrollment

          -  Isolation of B. cepacia from a respiratory tract culture within 6 months

          -  Severe nasal obstruction at the time of screening

          -  Receipt of any aerosolized experimental or investigational drugs within 1 month of
             enrollment

          -  Pregnancy (a negative pregnancy test must be documented prior to enrollment if
             applicable)

          -  Patients who have received treatment with nitric oxide for inhalation within 24 hours
             prior to study initiation or other investigational medications within 24 hours.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Sagel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2007</study_first_submitted>
  <study_first_submitted_qc>December 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2007</study_first_posted>
  <results_first_submitted>October 1, 2010</results_first_submitted>
  <results_first_submitted_qc>November 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 1, 2010</results_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inhaled Nitric oxide</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Nitric Oxide Low Dose</title>
          <description>Low dose group received Inhaled Nitric Oxide at 20 parts per million (ppm) via nasal cannula for 44 hours</description>
        </group>
        <group group_id="P2">
          <title>Inhaled Nitric Oxide High Dose</title>
          <description>High dose group received Inhaled Nitric Oxide at 40 ppm via nasal cannula for 44 hours.</description>
        </group>
        <group group_id="P3">
          <title>Nitrogen</title>
          <description>Nitrogen (Placebo) administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Nitric Oxide Low Dose</title>
          <description>Low dose group received Inhaled Nitric Oxide at 20 parts per million (ppm) via nasal cannula for 44 hours</description>
        </group>
        <group group_id="B2">
          <title>Inhaled Nitric Oxide High Dose</title>
          <description>High dose group received Inhaled Nitric Oxide at 40 ppm via nasal cannula for 44 hours.</description>
        </group>
        <group group_id="B3">
          <title>Nitrogen</title>
          <description>Nitrogen (Placebo) administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.9" spread="2.14"/>
                    <measurement group_id="B2" value="15.6" spread="2.33"/>
                    <measurement group_id="B3" value="17.7" spread="5.14"/>
                    <measurement group_id="B4" value="16.7" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Drug, Assessed by Change in Methemoglobin Levels</title>
        <description>Methemoglobin level assessments were measured through blood draws - hematology. This test measures the amount of methemoglobin (a type of hemoglobin that is unable to transport oxygen to tissues) in blood. Normal methemoglobin percentage range 1% - 2%.</description>
        <time_frame>Baseline and 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide Low Dose</title>
            <description>Low dose group received Inhaled Nitric Oxide at 20 parts per million (ppm) via nasal cannula for 44 hours</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Nitric Oxide High Dose</title>
            <description>High dose group received Inhaled Nitric Oxide at 40 ppm via nasal cannula for 44 hours.</description>
          </group>
          <group group_id="O3">
            <title>Nitrogen</title>
            <description>Nitrogen (Placebo) administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Drug, Assessed by Change in Methemoglobin Levels</title>
          <description>Methemoglobin level assessments were measured through blood draws - hematology. This test measures the amount of methemoglobin (a type of hemoglobin that is unable to transport oxygen to tissues) in blood. Normal methemoglobin percentage range 1% - 2%.</description>
          <units>Percent of Methemoglobin Level</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Methemoglobin Levels at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.14"/>
                    <measurement group_id="O2" value="0.5" spread="0.48"/>
                    <measurement group_id="O3" value="0.3" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methemoglobin Levels at 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.14"/>
                    <measurement group_id="O2" value="0.1" spread="0.10"/>
                    <measurement group_id="O3" value="0.4" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess the Difference in Sputum Bacterial Density Before and After NO Inhalation. Assess the Difference in Lower Airway Inflammatory Measures Before and After NO Inhalation</title>
        <time_frame>44 hours</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Oxygen Saturation</title>
        <description>Safety and tolerability of drug assessed by decreased oxygen saturation was measured through pulse oximeter, which measure the amount of oxygen in the blood.
Normal range percentage is 95 - 100%</description>
        <time_frame>Baseline and 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide Low Dose</title>
            <description>Low dose group received Inhaled Nitric Oxide at 20 parts per million (ppm) via nasal cannula for 44 hours</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Nitric Oxide High Dose</title>
            <description>High dose group received Inhaled Nitric Oxide at 40 ppm via nasal cannula for 44 hours.</description>
          </group>
          <group group_id="O3">
            <title>Nitrogen</title>
            <description>Nitrogen (Placebo) administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oxygen Saturation</title>
          <description>Safety and tolerability of drug assessed by decreased oxygen saturation was measured through pulse oximeter, which measure the amount of oxygen in the blood.
Normal range percentage is 95 - 100%</description>
          <units>Percent of oxygen saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxygen Saturation at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" spread="1.87"/>
                    <measurement group_id="O2" value="94.8" spread="2.14"/>
                    <measurement group_id="O3" value="95.5" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxygen Saturation at 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" spread="2.16"/>
                    <measurement group_id="O2" value="95.8" spread="3.19"/>
                    <measurement group_id="O3" value="97.0" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Decrease in forced expiratory volume in 1 second was measured through spirometer. Spirometer measures the volume of air inspired and expired by the lungs.</description>
        <time_frame>Baseline and 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide Low Dose</title>
            <description>Low dose group received Inhaled Nitric Oxide at 20 parts per million (ppm) via nasal cannula for 44 hours</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Nitric Oxide High Dose</title>
            <description>High dose group received Inhaled Nitric Oxide at 40 ppm via nasal cannula for 44 hours.</description>
          </group>
          <group group_id="O3">
            <title>Nitrogen</title>
            <description>Nitrogen (Placebo) administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Decrease in forced expiratory volume in 1 second was measured through spirometer. Spirometer measures the volume of air inspired and expired by the lungs.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Forced Expiratory Volume in 1 second at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.66"/>
                    <measurement group_id="O2" value="3.1" spread="1.07"/>
                    <measurement group_id="O3" value="3.0" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forced Expiratory Volume in 1 second at 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.66"/>
                    <measurement group_id="O2" value="3.1" spread="1.17"/>
                    <measurement group_id="O3" value="3.0" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Nitric Oxide Low Dose</title>
          <description>Low dose group received Inhaled Nitric Oxide at 20 parts per million (ppm) via nasal cannula for 44 hours</description>
        </group>
        <group group_id="E2">
          <title>Inhaled Nitric Oxide High Dose</title>
          <description>High dose group received Inhaled Nitric Oxide at 40 ppm via nasal cannula for 44 hours.</description>
        </group>
        <group group_id="E3">
          <title>Nitrogen</title>
          <description>Nitrogen (Placebo) administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis Media</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brahm Goldstein</name_or_title>
      <organization>INO Therapeutics</organization>
      <phone>908-238-6495</phone>
      <email>brahm.goldstein@ikaria.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

